Revised SPC: Episenta (sodium valproate) 500 mg prolonged-release granules

Update includes undesirable effects in the paediatric population, mainly severe liver damage under the age of 3 years. Pharmacokinetic data shows systemic clearance varies with age for below age 10 years. Ages up to 2 months have decreased clearance compared to adults.

Source:

electronic Medicines compendium